Duchenne Muscular Dystrophy (DMD) is a rare disorder characterized by progressive muscle wasting, weakness, and premature death. Remarkable progress has been made in genetic approaches, restoring dystrophin, or its function. However, the targeting of secondary pathological mechanisms, such as increasing muscle blood flow or stopping fibrosis, remains important to improve the therapeutic benefits, that depend on tackling both the genetic disease and the downstream consequences. Mitochondrial dysfunctions are one of the earliest deficits in DMD, arise from multiple cellular stressors and result in less than 50% of ATP content in dystrophic muscles. Here we establish that there are two temporally distinct phases of mitochondrial damage with depletion of mitochondrial mass at early stages and an accumulation of dysfunctional mitochondria at later stages, leading to a different oxidative fibers pattern, in young and adult mdx mice. We also observe a progressive mitochondrial biogenesis impairment associated with increased deacetylation of peroxisome proliferator-activated receptor-gamma coactivator 1 α (PGC-1α) promoter. Such histone deacetylation is inhibited by givinostat that positively modifies the epigenetic profile of PGC-1α promoter, sustaining mitochondrial biogenesis and oxidative fiber type switch. We, therefore, demonstrate that givinostat exerts relevant effects at mitochondrial level, acting as a metabolic remodeling agent capable of efficiently promoting mitochondrial biogenesis in dystrophic muscle.

Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy / M. Giovarelli, S. Zecchini, G. Catarinella, C. Moscheni, P. Sartori, C. Barbieri, P. Roux-Biejat, A. Napoli, C. Vantaggiato, D. Cervia, C. Perrotta, E. Clementi, L. Latella, C. De Palma. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 170(2021 Aug), pp. 105751.1-105751.14. [10.1016/j.phrs.2021.105751]

Givinostat as metabolic enhancer reverting mitochondrial biogenesis deficit in Duchenne Muscular Dystrophy

M. Giovarelli
Co-primo
;
S. Zecchini
Co-primo
;
C. Moscheni;P. Sartori;P. Roux-Biejat;A. Napoli;C. Perrotta;E. Clementi;C. De Palma
Ultimo
2021-08

Abstract

Duchenne Muscular Dystrophy (DMD) is a rare disorder characterized by progressive muscle wasting, weakness, and premature death. Remarkable progress has been made in genetic approaches, restoring dystrophin, or its function. However, the targeting of secondary pathological mechanisms, such as increasing muscle blood flow or stopping fibrosis, remains important to improve the therapeutic benefits, that depend on tackling both the genetic disease and the downstream consequences. Mitochondrial dysfunctions are one of the earliest deficits in DMD, arise from multiple cellular stressors and result in less than 50% of ATP content in dystrophic muscles. Here we establish that there are two temporally distinct phases of mitochondrial damage with depletion of mitochondrial mass at early stages and an accumulation of dysfunctional mitochondria at later stages, leading to a different oxidative fibers pattern, in young and adult mdx mice. We also observe a progressive mitochondrial biogenesis impairment associated with increased deacetylation of peroxisome proliferator-activated receptor-gamma coactivator 1 α (PGC-1α) promoter. Such histone deacetylation is inhibited by givinostat that positively modifies the epigenetic profile of PGC-1α promoter, sustaining mitochondrial biogenesis and oxidative fiber type switch. We, therefore, demonstrate that givinostat exerts relevant effects at mitochondrial level, acting as a metabolic remodeling agent capable of efficiently promoting mitochondrial biogenesis in dystrophic muscle.
Duchenne Muscular Dystrophy; givinostat; givinostat (PubChem CID: 9804991); metabolic agent; mitochondrial biogenesis; oxidative metabolism; trichostatin A (PubChem CID: 444732)
Settore BIO/14 - Farmacologia
Settore BIO/17 - Istologia
Settore BIO/16 - Anatomia Umana
29-giu-2021
Article (author)
File in questo prodotto:
File Dimensione Formato  
Pharmacological research.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 3.9 MB
Formato Adobe PDF
3.9 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pharmacological research supplementary.pdf

accesso riservato

Tipologia: Altro
Dimensione 877.43 kB
Formato Adobe PDF
877.43 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/859984
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact